Buying EM Up
Emerging market stocks are now on sale – but not everything that’s on sale is necessarily good value. What are some smart buys for EM… Read More »Buying EM Up
Investor
High Times, Weighty Issues
A number of factors – including this new one – have weighed on Canadian cannabis stocks this year despite the buzz surrounding impending legalization. Does… Read More »High Times, Weighty Issues
Reconsider Bypassing These Biotechs
These two biotech companies are big established players rather than exciting start-ups, which may help explain why they find themselves underappreciated by investors right now.… Read More »Reconsider Bypassing These Biotechs
Trading Midterm Meddling Fears
Amid ever-growing concerns about potential meddling in November’s midterm elections, Goldman Sachs is pointing to cybersecurity stocks as a compelling short-term bet for investors –… Read More »Trading Midterm Meddling Fears
Better Know This New Cannabis IPO
Canada-based Tilray is the latest cannabis firm to file for an initial public offering on the NASDAQ. Here’s a look at this new cannabis stock… Read More »Better Know This New Cannabis IPO
Tops Under 10
Value, growth, strong EPS revisions, profitability and strong momentum – all for under $10? That’s what these five stocks – including a healthcare sector standout… Read More »Tops Under 10
Healthy Speculation
This women-focused medical device stock – the author’s favorite speculative stock for 2018 – has had an impressive run so far this year. Here are… Read More »Healthy Speculation
Everything ESG
While those who deliberately apply an environmental, social and governance lens to their investing are still a minority, ESG investing is a rapidly growing trend… Read More »Everything ESG
When “Zero Tolerance” Means Big Money
However you feel about the Trump administration’s “zero tolerance” border policy (and the resultant detention of scores of adult and child migrants), it is expected… Read More »When “Zero Tolerance” Means Big Money
Bargain Bin & Analyst Adored
These three stocks – including a clinical-stage biotech with a still-promising drug candidate – may be under-performing at the moment, but some of Wall Street’s… Read More »Bargain Bin & Analyst Adored